Material Event (Form 8-K)

Item 8.01 Other Events.

On March 13, 2026, Bone Biologics Corporation (the "Company") filed a prospectus supplement (the "Prospectus Supplement") with the U.S. Securities and Exchange Commission (the "SEC")in connection with the Company's "at the market offering" program for the offer and sale of up to $1,064,000 shares of the Company's common stock, par value $0.001 per share (the "Shares"), from time to time through H.C. Wainwright & Co., LLC ("Wainright"), as sales agent, pursuant to the Company's existing At The Market Offering Agreement (the "Sales Agreement"), dated September 27, 2024.

The Shares, if any, will be issued pursuant to the Prospectus Supplement, dated March 13, 2026, and the accompanying base prospectus, dated September 2, 2025, contained therein, which together form a part of the Company's "shelf" registration statement on Form S-3 (File No. 333-288290), as amended, initially filed by the Company with the SEC on June 24, 2025 and declared effective by the SEC on September 2, 2025.

The aggregate market value of the Shares eligible for sale under the Prospectus Supplement is currently $1,064,000, which is based on the limitations of General Instruction I.B.6 of Form S-3. The Company previously sold approximately $1.7 million of shares of common stock under the Sales Agreement pursuant to prior prospectus supplements and an accompanying base prospectus, dated July 11, 2022, contained therein, which together formed a part of the Company's prior "shelf" registration statement on Form S-3 (File No. 333-265872) filed by the Company with the SEC on June 28, 2022 and declared effective by the SEC on July 11, 2022 (the "Prior Registration Statement"). The Prior Registration Statement is no longer effective or being utilized in connection with the sale of Shares under the Sales Agreement.

A copy of the legal opinion as to the legality of the $1,064,000 of Shares issuable under the Sales Agreement and covered by the Prospectus Supplement is filed as Exhibit 5.1 attached hereto.

This Current Report on Form 8-K shall not constitute an offer to sell or the solicitation of an offer to buy the Shares discussed herein, nor shall there be any sale of such securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.